ACPA-negative rheumatoid arthritis: From immune mechanisms to clinical translation

The presence of anti-citrullinated protein autoantibodies (ACPA) is a hallmark feature of rheumatoid arthritis (RA), which causes chronic joint destruction and systemic inflammation. Based on ACPA status, RA patients can be sub-grouped into two major subsets: ACPA-positive RA (ACPA(+) RA) and ACPA-negative RA (ACPA(-) RA). Accumulating evidence have suggested that ACPA(+) RA and ACPA- RA are two distinct disease entities with different underlying pathophysiology. In contrast to the well-characterized pathogenic mechanisms of ACPA(+ )RA, the etiology of ACPA(-) RA remains largely unknown. In this review, we summarized current knowledge about the primary drivers of ACPA(-) RA, particularly focusing on the serological, cellular, and molecular aspects of immune mechanisms. A better understanding of the immunopathogenesis in ACPA(-) RA will help in designing more precisely targeting strategies, and paving the road to personalized treatment. In addition, identification of novel biomarkers in ACPA(-) RA will substantially promote early treatment and improve the outcomes. Copyright (c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Automated summary

This review summarizes the current knowledge about the primary drivers of ACPA(-) RA, focusing on the serological, cellular, and molecular aspects of immune mechanisms. A better understanding of the etiology of ACPA(-) RA will aid in personalized treatment design and improve early treatment and outcomes.